Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

Repligen Corporation announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities.

4 Feb 2010

Ecolab launches EnCompass Environmental Hygiene program to improve patient room hygiene

Ecolab Inc. today announced the launch of its new EnCompass™ Environmental Hygiene program, a comprehensive clinical program that helps hospitals improve patient room hygiene and prevent the spread of infections.

1 Feb 2010

One-third of dairy products exceed microbe contamination levels, says study

One-third of samples of milk and dairy products analysed in various restaurants exceed the microbe contamination limits set by the European Union, according to a study carried out by researchers from the University of Valencia (UV). The experts advise against keeping milk in jugs and suggest that these foodstuffs need to be better handled.

30 Jan 2010

Wrestlers are at higher risk for skin infections than other athletes

As high school and college wrestlers return to the mats in preparation for February tournaments and post-season championships, their risk for the skin infection Methicillin-Resistant Staphylococcus Aureus (MRSA) increases significantly.

30 Jan 2010

Good bacteria may help counteract negative effects of antibiotics in humans

Scientists have long pondered the seeming contradiction that taking broad-spectrum antibiotics over a long period of time can lead to severe secondary bacterial infections. Now researchers from the University of Pennsylvania School of Medicine may have figured out why.

27 Jan 2010

Antibiotics may be effective in fighting MRSA infections

Researchers at the University of Illinois at Chicago and Israel's Weizman Institute of Science have found that two antibiotics working together might be more effective in fighting pathogenic bacteria than either drug on its own.

27 Jan 2010

Scientists map origin of MRSA, technology could help understanding of other diseases

"Scientists have found a way to track minutely-differing strains of the 'superbug' MRSA [methicillin-resistant Staphylococcus aureus] as they spread between people and across the globe, a finding that could aid efforts to control the deadly bacteria," Reuters/ABC News reports (Kelland, 1/21).

23 Jan 2010

Current research suggests flu may predispose to secondary bacterial infections

Current research suggests that the flu may predispose to secondary bacterial infections, which account for a significant proportion of mortality during flu pandemics. The related report by Lee et al, "A mouse model of lethal synergism between influenza virus and Haemophilus influenzae," appears in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Kenta Biotech today announced an agreement with Rentschler Biotechnologie for the development of a fully human monoclonal antibody against methicillin-resistant Staphylococcus aureus (MRSA).

18 Jan 2010

Studies suggest ways to prevent post-surgical infections in hospitals

Two new studies are suggesting relatively simple ways in which hospitals can prevent many post-surgical infections by killing bacteria the patients themselves bring in, according to Monday's New York Times.

13 Jan 2010

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

Inhibitex, Inc. today announced that its collaborator, Pfizer, Inc., has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus (S. aureus) vaccine (SA3Ag) in healthy adults.

12 Jan 2010

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

ViroPharma Incorporated today announced that it has signed an agreement with Sanquin Blood Supply Foundation for rights to develop, file regulatory dossiers, and commercialize Cinryze(TM) (C1 esterase inhibitor [human]) for hereditary angioedema (HAE) as well as for potential new indications in certain European and rest of world (ROW) territories.

12 Jan 2010

Sorrento Therapeutics, Scripps Research Institute announce antibody development collaboration

Sorrento Therapeutics, Inc. today announced an antibody discovery and development collaboration with The Scripps Research Institute, La Jolla, CA. Under the terms of the agreement, Sorrento Therapeutics obtains an exclusive, worldwide license to the Institute's novel technology, based on quorum sensing, for the prevention and treatment of Staphylococcus aureus ('Staph') infections, including Methicillin-resistant Staph. aureus (MRSA).

12 Jan 2010

LSUHSC receives $2.1 million grant for pneumonia research

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to further his work on a discovery that plays a critical role in the body's defense against pneumonia.

8 Jan 2010

J&JPRD receives FDA Complete Response Letter for ceftobiprole

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections.

30 Dec 2009

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

Forest Laboratories announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca’s announced acquisition of Novexel, S.A.

24 Dec 2009

Researchers develop new approach for treating and healing skin abscesses

Researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a new approach for treating and healing skin abscesses caused by bacteria resistant to most antibiotics.

23 Dec 2009

New community-associated strain of MRSA more apt to cause serious problems

The often feared and sometimes deadly infections caused by MRSA - methicillin-resistant Staphylococcus aureus - are now moving out of hospitals and emerging as an even more virulent strain in community settings and on athletic teams, and raising new concerns about antibiotic resistance.

23 Dec 2009

Staphylococcus aureus causes far more serious infections than previously realised

Staphylococcus aureus causes far more serious infections than previously realised, with more than 3,000 Swedes affected every year, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

23 Dec 2009

Durata Therapeutics acquires Vicuron Pharmaceuticals

Durata Therapeutics, Inc. announced today that it has acquired Vicuron Pharmaceuticals from Pfizer (PFE). Durata is a newly formed biopharmaceutical company that was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners.

21 Dec 2009

Staphylococcus aureus News and Research

Further Reading

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

Ecolab launches EnCompass Environmental Hygiene program to improve patient room hygiene

One-third of dairy products exceed microbe contamination levels, says study

Wrestlers are at higher risk for skin infections than other athletes

Good bacteria may help counteract negative effects of antibiotics in humans

Antibiotics may be effective in fighting MRSA infections

Scientists map origin of MRSA, technology could help understanding of other diseases

Current research suggests flu may predispose to secondary bacterial infections

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Studies suggest ways to prevent post-surgical infections in hospitals

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

Sorrento Therapeutics, Scripps Research Institute announce antibody development collaboration

LSUHSC receives $2.1 million grant for pneumonia research

J&JPRD receives FDA Complete Response Letter for ceftobiprole

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

Researchers develop new approach for treating and healing skin abscesses

New community-associated strain of MRSA more apt to cause serious problems

Staphylococcus aureus causes far more serious infections than previously realised

Durata Therapeutics acquires Vicuron Pharmaceuticals

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News